Roivant Sciences Ltd. (ROIV)
$
14.08
-0.33 (-2.34%)
Key metrics
Financial statements
Free cash flow per share
-1.2622
Market cap
9.4 Billion
Price to sales ratio
404.7383
Debt to equity
0.0229
Current ratio
40.5367
Income quality
0.9770
Average inventory
0
ROE
-0.1013
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London, United Kingdom, founded in 2014. The company is focused on researching and developing innovative medicines across a range of therapeutic areas, including the treatment of solid tumors, sickle cell diseases, hypophosphatasia, and various skin conditions such as psoriasis, atopic dermatitis, and vitiligo. Additionally, Roivant is advancing therapies for serious conditions like myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. In the fiscal year 2024 the company recorded a notable revenue of $29,053,000.00 showcasing its steady growth through its diverse portfolio of product candidates. The cost of revenue for the company is $911,000.00 reflecting its production and operational expenses associated with its developmental pipeline. Furthermore, the weighted average number of diluted shares outstanding is 725,396,000.00 which indicates the potential dilution effects on existing shareholders. The diluted EPS is -$0.24 providing insight into the company's earnings performance, adjusted for outstanding options and other securities. In terms of investment potential, the stock is affordable at $14.08 making it suitable for budget-conscious investors looking for opportunities in the biopharmaceutical arena. With a mid-range market capitalization of $9,614,978,560.00 the company is viewed as a steady performer within its sector. It operates as a key player in the Biotechnology industry, actively contributing to the overall market landscape with its innovative research and development efforts. The stock enjoys a high average trading volume of 6,340,029.00 indicating strong liquidity, which can be appealing for investors concerned with the ability to enter or exit positions. Additionally, being part of the Healthcare sector, Roivant Sciences is driving innovation and growth, further enhancing its attractiveness to potential stakeholders.
Is Roivant Sciences Ltd. (ROIV) a good investment?
Investing in Roivant Sciences Ltd. (ROIV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Roivant Sciences Ltd. (ROIV)'s stock forecast?
Analysts predict Roivant Sciences Ltd. stock to fluctuate between $8.73 (low) and $14.48 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Roivant Sciences Ltd.'s market capitalization?
As of 2025-09-12, Roivant Sciences Ltd.'s market cap is $9,614,978,560, based on 682,882,000 outstanding shares.
How does Roivant Sciences Ltd. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Roivant Sciences Ltd. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Roivant Sciences Ltd. (ROIV) stock?
To buy Roivant Sciences Ltd. (ROIV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ROIV. Place an order (Market, Limit, etc.).
What is the best time to invest in Roivant Sciences Ltd.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Roivant Sciences Ltd. perform in the last earnings report?
Revenue: $29,053,000 | EPS: -$0.24 | Growth: -104.32%.
Where can I find Roivant Sciences Ltd.'s investor relations reports?
Visit https://roivant.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Roivant Sciences Ltd.?
You can explore historical data from here
What is the all-time high and low for Roivant Sciences Ltd. stock?
All-time high: $16.76 (2021-12-20) | All-time low: $2.52 (2022-05-12).
What are the key trends affecting Roivant Sciences Ltd. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant's first time being named to this prestigious list, coming in at 28th place in the small & medium category. Earning a spot means that Roivant is one of the best companies to work for in the country.
seekingalpha.com
Roivant Sciences Ltd. (NASDAQ:ROIV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 5:35 PM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Albert Wong - Morgan Stanley Presentation Albert Wong Good afternoon, everybody, and thanks for being here powering through towards the end of the day.
fool.com
Commercial-stage biotech Roivant Sciences (ROIV -2.79%) started the trading week with an earnings release. In retrospect, that might not have been the wisest move.
seekingalpha.com
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Matthew Gline - CEO & Director Stephanie Lee Griffin - Vice President of Special Projects Conference Call Participants Corinne Johnson - Goldman Sachs Group, Inc., Research Division David Reed Risinger - Leerink Partners LLC, Research Division Douglas Dylan Tsao - H.C.
zacks.com
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23.
globenewswire.com
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.
seekingalpha.com
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci Capital Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
zacks.com
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.16.
zacks.com
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
See all news
